News

In July, ixazomib was granted accelerated assessment by the EMA’s Committee for Medicinal Products for Human Use (CHMP). The MAA was based on the results of the first

Eteplirsen is designed to address the underlying cause of DMD by allowing the production of a functional dystrophin protein. The company said that data from clinical trials of

Ofatumumab, a fully human monoclonal antibody currently being designed for relapsing remitting multiple sclerosis (RRMS) and other autoimmune indications, targets CD20 and is administered by subcutaneous injection. Previously,

Paliperidone palmitate once-monthly is an atypical long-acting injection to treat schizophrenia and is now approved in more than 80 countries, while the drug is marketed as Xeplion in

BTA585 is an orally bioavailable compound being developed to treat respiratory syncytial virus (RSV) infections in children, the elderly and immunocompromised patients. The Phase I SAD trial has

A six-month review period has been assigned for the sBLA and the Prescription Drug User Fee Act (PDUFA) date is expected to be in the first quarter of

Plitidepsin is an investigational anticancer agent of marine origin, originally obtained from the ascidian Aplidium albicans. As part of the deal, PharmaMar will receive an upfront payment, royalties

Axalimogene filolisbac is Advaxis’s investigational Lm Technology immunotherapy, while durvalumab is MedImmune’s investigational anti-PD-L1 immune checkpoint inhibitor. Around 66 patients will be included in the two-part, open-label Phase

TLRs are said to be important class of proteins that play a crucial role in the innate immune system and scientific evidence links aberrant TLR activation and signaling